USP updates on Excipient Monograph Modernization and FDA Modernization Task Group list
Catherine M. Sheehan, M.S., M.S.Sr. Director, Excipients US [email protected]
ExcipientFest Baltimore, MD April 30-May1, 2013
USP Monograph Modernization Initiative
– Background
USP Monograph modernization strategy and approaches
FDA Modernization Task Group (MMTG)/FDA ORA – Review the FDA Lists of priority excipients
USP Monograph modernization – Progress on NF Excipients– Collaborative efforts with stakeholders– USP Lab method development in collaboration with stakeholders
“Ethylene Glycol, Diethylene Glycol, and Triethylene Glycol in Ethoxylated Substances”
Topics
Primary driver is maintaining up-to-date quality standards to support USP’s commitment to public health
Need for modernization– Monographs have been official for several years, decades in some
cases
– Content does not reflect current expectations for procedures and acceptance criteria
– Complaints from the public
– General lack of specificity
Modernization is a subset of USP’s ongoing revision work, started using the term “modernization” in 2009
FDA Modernization Task Group ( Nov. 2010)
List of priority excipients - most recent, July 2012 list of 13.
USP Monograph Modernization
Benefits Strengthens the public standards
Moves from non-specific to specific procedures
Considers practical factors – removes unnecessary tests
– Safety/environmental issues such as eliminating use of chlorinated solvents
– hard to find equipment
Increases consistency across monographs
USP Monograph Modernization
ExcipientFest 2011: Keynote Speaker - Dr. Steven Wolfgang, Ph.D. , “A Vision for Total Excipient Control”
Calcium Benzoate (FCC) was identified as a potential monograph for modernization due to a nonspecific assay based solely on the titration of the metallic ions.
The monograph did not contain a method confirming the organic portion of the molecule.
USP R&D lab developed a HPLC method for a quantitative assay based on the amount of benzoic acid in the benzoate salts.
Two NF monographs Sodium Benzoate (NF and FCC), Potassium Benzoate (NF and FCC) were modernized using the same HPLC method.
Most importantly:
The USP Lab developed HPLC method showed that the commercial samples of Calcium Benzoate failed the HPLC assay.
Calcium Benzoate FCC Modernization
Overlaid Chromatograms of Calcium Benzoate Samples
AU
0.00
0.10
0.20
0.30
0.40
0.50
0.60
Minutes0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00
Ben
zoic
aci
d
USP Ca Benzoate RS
Commercial Ca benzoate sample
Diluent
Chromatographic conditions: HPLC method for benzoates assay
Calcium Benzoate USP Lab. Investigation
Method USP Calcium Benzoate RS Commercial Calcium Benzoate
Titration 99.3% 99.6% (CofA)
HPLC(% w/w Assay)
99.3% 43.8% Propionic acid Peak observed
LOD 15.2% 10.7% (5.1% in CofA)
FT-IR Typical spectrum Peaks in ~2900 cm-1
(asymmetric C-H stretch)
1H NMR 100% benzoate 36% benzoate : 64% propionate (mol % basis)
Raman (Dispersive and FT)
Typical spectrum Peaks specific to propionate
AA Spectroscopy 11.0% of Ca 16.0% Ca
MW # Water %Water Theor %Ca
336.35 3 16.1 11.9
300.33 1 6.0 13.3
282.31 0 0.0 14.2
9
Calcium Benzoate and Calcium Propionate Structures
Calcium Propionate
Formula C6H10CaO4
Weight 186.22 Preservative, mold inhibitor
Calcium Benzoate
Formula C14H10CaO4 · nH20
Weight Anhydrous 282.31Preservative, antimicrobial agent
Compound Name Amount, g
MW, g/mol
Cost*, $
Ca Benzoate 100 336.35 129.84
Ca Propionate 100 186.22 30.30
*Fisher
Potassium Benzoate NF and Sodium Benzoate NF - PF 38(3)
Assay: Proposal to replace the current nonspecific titrimetric procedure based
on the titration of the metallic ions with a stability-indicating HPLC quantitative
procedure based on the amount of benzoic acid in the benzoate salts.
Definition: revise the acceptance criteria from “NLT 99.0% and NMT 100.5%” to
“NLT 99.0% and NMT 101.0%”. The upper limit of the Assay acceptance criteria
range is widened by 0.5% to account for the performance of the HPLC method.
Identification:
Replace the wet chemistry test for Benzoate <191> with the HPLC Assay method by RT agreement with the major peak.
Add an Infrared Absorption <197K> test.
Add a USP Reference Standards section containing USP Potassium Benzoate
RS, USP Benzoic Acid RS, and USP Salicylic Acid RS.
The Importance of USP Compendial Monograph Modernization
USP’s greatest challenge is obtaining updated procedures and acceptance criteria—manufacturers are encouraged to submit proposals to USP
Pace of monograph modernization is linked to availability of procedures
Excipient monograph modernization is a major initiative in the 2010-2015 revision cycle.
USP is devoting resources to this effort -
USP expansion includes establishment of global laboratory sites.
Collaboration with FDA, industry and other stakeholders is key to advancing the work.
USP Monograph Modernization
April 24, 2010
Resolutions Supporting Public Health Adopted by Convention
Strengthen USP’s Relationship with the U.S. Food and Drug
Administration. USP resolves to strengthen its relationship with the
Food and Drug Administration (FDA), and work with FDA and other
public and private stakeholders to explore mechanisms to enable
USP to provide and maintain up-to-date national standards for
legally marketed drugs and excipients in the United States.
2010-2015 revision cycle: USP Commitment
Continued Collaboration with FDA and Industry
Prioritization
Timing considerations
Monograph Modernization Strategy and Approaches
Modernization of monographs achieved by
– Replacing outdated technology and methodology with more current procedures
– Adding critical tests to the monograph
– Deleting non-value added tests, as needed (e.g., odor test, melting point)
Follows the USP standards-setting process (i.e., with publication in PF for 90-day comment period)
FDA to provide input to USP on prioritization (FDA MMTG and ORA lists)
Other considerations
–Use procedures from other pharmacopeias–May need RS materials –Revising the monograph “family”, as needed
USP Monograph Modernization Process
No Identification or non-specific Identification procedures
No Assay or non-specific Assay procedures
Stainless steel/packed column GC procedures
Titration to GC/HPLC where appropriate
No impurity test, (e.g., Povidones and peroxides)
Safety-related concerns (e.g., chlorinated solvents).
Labeling deficiencies , e.g., when used in parenteral/injectable grade applications
–Missing specific tests to control quality (e.g., Microbial/BE)
Excipient Monograph Modernization: Prioritization of Categories
Monograph and Reference Material Procurement and Development
Traditional donor model (‘externally sourced’)– Very difficult to engage sponsors
USP laboratories (‘internally sourced’)– New technologies in Rockville labs (eg, UPLC, High Res. MS)
– Extensive testing facilities in India for reference procedure development
– Collaborative testing sites in India, China and Brazil (in addition to Rockville)
– MOU with China - excipient monograph development
FDA (CRADA: ORA Labs)
Adapt/Adopt (Other Pharmacopeias e.g. B.P., ChP)
Monograph Updating Strategies
6
AnalyticalLaboratories
USP
USP Global Laboratory Capabilities
Global Laboratory Capacity Square Footage
USP US 43,000 sq. ft.
USP India 65,000 sq. ft.
USP China Current: 3,000 sq. ft.Jan ‘14: 55,000 sq. ft.
USP Brazil 6,400 sq. ft.
Global USP Laboratory Capacity
USA Laboratory Capacity Square Footage
Research & Development 15,500 sq. ft.
Biologics and Biotechnology
4,500 sq. ft.
Reference Standards Laboratory
19,000 sq. ft.
Dosage Form Performance 4,000 sq. ft.
Research and Development Laboratories– Monograph Development and Modernization
• Chemical Medicines, Excipients, Foods, Dietary Supplements, Biologics
Isolation and Characterization of Impurities
Complex Materials Characterization/Authentication
– Dosage Form Performance Lab
Reference Standards Laboratory– Testing of Candidate Reference Standards
• Identification; Structure Verification, Purity determination
– Investigations / Complaints – Continued Suitability for Use testing
New to USP Technology Program
Dissolution Research and PVT RS Development
19
USP US Laboratory Facility
R&D Laboratory Capabilities
Biologics Laboratory•Cell biology and bioassay•Protein Analysis•Enzyme Assays•Amplification (QPCR, RT-PCR)•Nucleic Acid Analysis
Analytical Laboratory•NMR•MS•MS/MS•LCMS•IR, Raman, FTIR•ICP/ICP-MS
•HPLC, UHPLC•GC, GC/MS•IC, Titration, TLC•TGA, DSC•Vapor Sorption Analysis•KF, LOD, ROI
Dosage Form Laboratory•Dissolution•PVT Formulation
RS Candidates are evaluated on the following:
Appearance
Identification Tests
(IR, NMR, MS, Chromatography)
Purity tests (mass balance )
– Chromatographic purity (HPLC, GC) – Inorganic contaminants determination (ROI)– Volatiles (KF, LOD, GC-Headspace)
Indirect purity tests
– Melting range – Specific rotation
– Refractive index
USP US Activities – Reference Standards Laboratory
Analytical Techniques Used in RSL:– Chromatography
– HPLC, UHPLC, GC, IC, TLC– Spectroscopy
– FTIR, UV, MS, NMR– Other Compendial Techniques
– KF, LOD, TGA/DSC, MP, RI, OR, ROI, CHN
- ISO 9001:2008 certified (BSI)
- ISO 17025:2005 certified (ACLASS)
Quality Systems
Excipients FDA High Priority List – Monograph Modernization Task Group (MMTG) listMonograph List FDA recommend Modernization progress
PovidoneCrospovidoneCopovidone
Letter 1 Nov 2010 Replace non-specific N determination Assay <461> Kjeldahl methodAdd Peroxide test
Povidones Expert Panel formedJune 2011.PDG S6 – Peroxide , hydrazine tests added
Talc Letter 1 Nov 2010 Replace Limit of Asbestos and update Definition and Labeling
Talc Expert Panel formedAim: publish Stim article in PF 39(6)
Butylated Hydroxyanisole
Lette
r 3
Jul 2
012
Lack
of s
peci
fic ID
tes
t
Butylated Hydroxytoluene USP labs – Add Chromatographic Assay – ID test add RT agreement
Dextrose Excipient
Silicon Dioxide (Colloidal)
Titanium Dioxide
Croscarmellose Sodium(Croslinked CMC sodium)
USP labs – IR test
CarboxymethylcelluloseSodium (CMC sodium)
Gelatin PDG Stage 6 published as RB
Guar Gum USP labs: ID: chem. comp. by TLC
Microcrystalline Cellulose USP labs – ID by IR test
Pregelatinized Starch
USP labs – ID:IR and TLC methodsShellac
Harmonization with PDG S6 Mg(St)2Published in PF 39(4)
Calcium Stearate
FDA High Priority Excipients - ORA list of deficiencies -
Monograph Deficiency Modernization progress
Aspartame “Replace non specific assay titration and add impurities test” HPLC Procedure For LIMIT OF
5-BENZYL-3,6-DIOXO-2-PIPERAZINEACETIC ACID . USP Labs: EVALUATE FOR USE INASSAY
Titanium Dioxide (also on MMTG list)
“Assay method is out of date, involves digestion with concentrated acids, etc.” FDA recommendation: Use advanced methods for quantitation of TiO2 (Ref: "A novel volumetric method for quantitationof titanium dioxide in cosmetics," Journal of Cosmetic Science, Volume 57, Issue 5, Pages377-383, 2006).
USP Labs: evaluate method
Glycerin “Current assay method for glycerin is out of date (periodate method)).” FDA recommendation. Replace periodate method with quantitative GC method (USP method for determination of quantities of DiethyleneGlycol and Ethylene Glycol is a GC method).
Glycerin Expert Panel formed in Dec. 2012PDG monographUSP labs: evaluate method
Crospovidone(also on MMTG list)
“Test method for Peroxides is outdated”
FDA recommendation: Quantitative determination of trace levels of hydrogen peroxide in crospovidone and a pharmaceutical product using HPLC with coulometric detection." International Journal of Pharmaceutics, Volume 375, Issues 1–2, 2009, Pages 33–40).
Povidones Expert Panel formed in Jan. 2011PDG monographUSP Labs: evaluate method
Monograph Completed PF Sponsor Modernization Priority
Compressible Sugar PF38(6) USP Lab/Industry ID by FTIR, Assay by HPLC USP weblist
Confectioner’s Sugar PF38(6) USP Lab ID by Spec Rot, Assay by HPLC Content of Sucrose USP weblist
Sugar Spheres PF38(6) USP Lab ID by Spec Rot, Assay by HPLC USP weblist
Lecithin PF38(6) Industry/USP labsID by updated TLC for chem comp. Assay, add Content of Phospholipids by HPLC-ELSD. Update the Labeling requirements
USP weblist
Squalane PF38(6) USP LabsID by RT agreement with Assay. Assay by GC.
USP weblist
Ascorbyl Palmitate PF38(6) USP LabsID by RT agreement with Assay
Assay from titration to HPLC USP weblist
Gelatin (H6)PF37(1) Revision
BulletinEP/JP/USP (PDG)
Stage 6 posted on USP website/harmonizationSept 2012, official April 2013
USP weblist/MMTG llist
High Fructose Corn Syrup PF39(1) (IRA) Industry/USP lab Content of Fructose USP weblist
Succinic Acid PF39(2) USP LabsID by RT agreement with Assay.Assay from titration to a HPLC
USP weblist
Cholesterol PF39(3) USP Labs Add ID by FTIR USP weblist
Purified Stearic Acid PF39(1) PDG S6 Stearic acid ID by RT agreement with Assay. Assay by GC cap USP weblist
Sodium Stearate PF39(3)Mg (St)2 PDG S6/USP labs
ID by RT agreement with Assay. Assay by GC cap USP weblist
Calcium Stearate PF39(3)Mg (St)2 PDG S6/USP Labs
ID A from wet-chemistry to FTIRID by RT agreement with Assay. Assay by GC cap
USP weblist/MMTG llist
Excipient modernizations for USP 37-NF 32
Monograph Modernization in progress Stakeholder Priority list
Methylparaben sodium Add Assay and related substances USP Labs/PDG S6 USP weblist
Propylparaben sodium Add Assay and related substances USP Labs/PDG S6 USP weblist
Mannitol (H) Introduce FTIR in ID test USP Labs/EP USP weblist
Polysorbate 80Introduce FTIR in ID test USP Labs/EP USP weblist
Guar Gum Update ID USP Labs/EP/Industry USP weblist/MMTG llist
Anise oil Update Definition /Assay by GC USP Labs/EP USP weblist
ShellacIntroduce FTIR and chemical composition TLC in ID test
Industry/USP Labs USP weblist/MMTG llist
Butylated HydroxytolueneIntroduce ID by RT . Add Assay -HPLC /GC methods under evaluation
USP Labs USP weblist/MMTG llist
Sucrose Introduce FTIR in ID testUSP Labs
USP weblist
Potassium SorbateIntroduce FTIR in ID test. Replace Assay by titration with GC
USP LabsUSP weblist
Glycerin Expert panel formed to develop S3 draft Industry FDA ORA list
Aspartame Replace Assay titration with HPLC USP labs FDA ORA list
Microcrystalline Cellulose Introduce FTIR in ID test USP labs FDA MMTG list
Croscarmellose Sodium(Croslinked CMC sodium)
Introduce FTIR in ID test USP labs FDA MMTG list
Carboxymethylcellulose Sodium (CMC sodium)
Introduce FTIR in ID test USP labs FDA MMTG list
Excipient modernizations in development
Chinese Pharmacopoeia Commission (ChP) - USP MOU Working group #1 – Documentary standards and Reference Materials – Excipients
– 13th meeting of MOU discussion. USP first visit to China in 1990. Initial MOU signed 2005
– Cooperate to develop quality standards for excipients in the global supply chain
– Establish the 22 nd Medicines Expert Committee East Asia Expert committee (EAEC) to work on development of excipient monographs to support the Medicines Compendium and for potential adoption by both ChP and NF.
– Dr Jiasheng Tu serves as Chair of the ChP Commission Expert Committee on Excipients and a member of the Expert committee of Center for Drug evaluation, SFDA. He is also Chair of the USP EAEC, China and a member of the USP Excipient EC, USA.
– Ms. Han Peng is the ChP liaison to the MCEA EC.
– Provincial lab support.
Chinese Pharmacopoeia Commission – USP MOU
ChP also modernizing several excipients in ChP 2010 that appear on the USP web list
ChP reviewed USP’s Excipient modernization web list
USP Excipient Expert Committee agree to start work on the following excipients
– Calcium Stearate (USP Lab work complete)– Calcium Sulfate– Carnauba Wax– Cholesterol (USP Lab work complete)– Diethyl Phthalate– Ethyl Acetate– Hydrogenated Castor Oil (USP Lab in dev.)– Maltodextrin (Working with Industry) – Monobasic Potassium Phosphate– Sulfuric Acid– White Wax– Xanthan Gum (USP Lab in dev.)
ChP-USP work on excipient modernization
USP Rockville reviewed the ChP list of 150 monographs targeted for development in ChP 2015 edition
USP and ChP selected 15 new excipient monographs for development
Nine are at various stages of development:
– Sodium Oleate– Cholic acid– Potasium stearate – Aluminum stearate – Sodium Caseinate – Benzyl paraben– Rosin – Dimethyl ether – Sodium nitrate
First 6 by 22 nd MC EAEC and USP China Lab
Last 3 by 22nd MC EAEC and CFDA -China provincial labs.
ChP-USP work on excipient monograph development
USP effortsUSP will continue to use its lab resources and engage stakholders
Sourcing procedures from other compendia, literature, other
Form Expert Panels, as needed, to address specific topics
Collaboration Explore possible lab support from CRADA with the FDA
Collaborate with FDA MMTG, refine priorities as needed
ChP - USP list of 15 new monographs and12 modernizations
Engage with other stakeholders
Moving Forward
• Excipient monograph modernization is a major initiative in the 2010-2015 revision cycle
• USP is devoting resources to this effort – new laboratory capabilities
• Collaboration with FDA, industry and other stakeholders is key to advancing the work
• Long-term goal is to implement a regular monograph review process to monitor the needs for further modernization
• USP’s Challenges
– Obtaining procedures and acceptance criteria– Prioritizing and requesting submissions - with FDA involvement ,
the hope is that industry is much more likely to come to the table
Conclusion
Upcoming USP – Excipient related meetings
• The USP ExcipientsStakeholder Forum
– Planned for June 7, 2013,USP Headquarters, Rockville, Maryland
– Objective: focus on science and compliance topics related to pharmaceutical excipients.
– Industry and stakeholder participation in USP's public standards-setting process is essential to the development of authoritative, relevant USP–NF monographs.
– Free registration -open to all users, makers and distributors.
– Web based allowing greater access and global participation.
• USP Science & Standards Symposium – Excipients track
– September 18–19, 2013, Baltimore Marriott Waterfront, Baltimore, Maryland
– Excipient track• Track Session 1: Modernization of NF Excipient monographs.
• Track Session 2: Developing / harmonizing excipient monograph standards.
• Track Session 3: Defining Excipient Quality
Ethylene Glycol, Diethylene Glycol, and Triethylene Glycol in Ethoxylated Substances.
USP Lab. Method development in collaboration with stakeholders
K. Gilbert, C. Chisolm, K. Ramakrishna, H. Wang, E. Biba and S. WahabSeparation Sciences Laboratory, U.S. Pharmacopeia, Rockville, MD 20852
Background
Samples
Method
Results
Conclusion
Outline
34
USP currently undergoing a resolve to modernize and strengthen the monographs
of ethoxylated substances by adding testing for ethylene glycol (EG), diethylene
glycol (DEG), and triethylene glycol (TEG). An analytical gas chromatographic
procedure was developed and validated by our laboratory.
Currently, a general chapter <469> will be proposed in PF 39(4)[June-July 2013] for
public comment to include testing for ethylene glycol, diethylene glycol and
triethylene glycol in ethoxylated substances.
USP took into consideration the EP chapter 2.4.30. ETHYLENE GLYCOL AND
DIETHYLENE GLYCOL IN ETHOXYLATED SUBSTANCES and industry methods
in the development of the USP chapter.
Following testing, this method was found to be applicable to 17 different excipient
monographs.
Background
35
Ethoxylation is a manufacturing process in which ethylene oxide is combined with alcohols and phenols to produce surfactants. The most common surfactants are synthesized by the ethoxylation process, which include alcohol ethoxylates, alcohol propoxylates and alcohol ethoxysulfates.
Ethoxylation Definition
36
Ethylene oxide
Ethoxylated Substances in the Pharmaceutical Industry
37
Ethoxylated substances such as polyoxyl fatty acid esters, polyethylene glycols and polysorbates are commonly used as pharmaceutical excipients in different formulations.
Example: Tween 20 (Polysorbate 20)
x+y+w+z =20
Blank: acetone
IS (Internal standard solution): 40 μg/mL solution of 1,3-butanediol in acetone.
Standard Solution: 25 μg/mL of EG and 40 μg/mL each of DEG and TEG diluted in IS.
EG Sensitivity Solution: 1.2 μg/mL of EG, 2.0 μg/mL of DEG and TEG diluted in IS.
DEG and TEG Sensitivity Solution: 0.8 μg/mL of EG and 1.2 μg/mL of DEG, TEG diluted in IS.
Sample Solutions: 40 mg/mL of the ethoxylated substance sample diluted in IS.
Sample Preparations
38
Instrument: Gas chromatograph with flame ionization detectionCarrier Gas: HeliumLiner: Straight liner with wool Injector port: 270°Injector mode: SplitSplit ratio:2:1 Septum Purge Rate: 5 mL/minInjection volume: 1.0 μL Column: Restek Rtx-50; 0.53-mm x 30-m fused-silica analytical column; 1.0-μm layer of phase G3Column Mode: Constant flow Column flow rate: 5.0 mL/minOven Program:
Initial Temp.(°C) Time Ramp (°C/min) Final Temp.(°C) Hold time at Final Temp.(min.) 40 10 60 560 10 170 0 170 15 280 0, 60
Detector Temperature: 290°
Method
39
The following ethoxylated compounds were tested and validated in four groups as follows:
Polysorbates Polyethylene Glycols Solid Polyoxyls Miscellaneous Liquids
Polysorbate 20 PEG 200 Polyoxyl 8-stearate Octoxynol-9 Polysorbate 40 PEG 300 Polyoxyl 20 Cetostearyl ether Nonoxynol-9Polysorbate 60 PEG 400 Polyoxyl 15 Hydrostearate PEGMME-350Polysorbate 80 PEG 600 PEGMME-550
Polyoxyl 35 castor oil
Compounds Tested
40
Typical Chromatogram of Standard Solution
41
uV
-200000
0
200000
Minutes
5.00 10.00 15.00 20.00 25.00
EG
–62
0 pp
m
DE
G-
1000
ppm
TE
G-
1000
ppm
IS-
40 p
pm
Polysorbate Chromatograms
42
pA
0.00
200.00
400.00
600.00
800.00
1000.00
1200.00
Minutes
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00 55.00 60.00 65.00 70.00 75.00 80.00
Polysorbate 20
Polysorbate 40
Polysorbate 60
Polysorbate 80
DE
G
EG
IS
TE
G
Concentration of EG, DEG, and TEG Found in Polysorbates
43
Average Concentrationa (ppm)
EG DEG TEG
Commercial A Polysorbate 20 12.8 10.0 15.7
Commercial A Polysorbate 40 2.0 312 717
Commercial A Polysorbate 60 15.6 12.0 29.1
Commercial A Polysorbate 80 5.7 8.9 20.9
Commercial B Polysorbate 20 9.5 12.2 26.7
Commercial B Polysorbate 80 4.4 7.7 20.6aAverage of two determination
Recovery Rates of EG, DEG, and TEG in Some Samples
44
Compound PolysorbatesRecovery Rates
Solid Polyoxyl SamplesRecovery Rates
Miscellaneous Liquid SamplesRecovery Rates
EG 80-107% 106- 115% 109- 118%
DEG87-115% 88- 101% 93-111%
TEG 82-105% 92- 118% 100-116%
GroupAverage:EGDEGTEG
90%98%90%
110%101%103%
112%105%106%
•The developed method has a broad applicability.
•EG, DEG, and TEG are well separated from each other and from other peaks found in matrix.
• LOD solution 0.27 µg/mL of EG, 0.4 µg/mL of DEG and TEG-(S/N) 10- very sensitive
•Good precision- ≤ 2.0%
•Has not been introduced into specific monographs.
__________________________________________________
Conclusion
45